CHMP recommends approval of Reblozyl for transfusion-dependent anemia due to very low-, low- and intermediate-risk myelodysplastic syndromes and transfusion-dependent anemia associated with beta thalassemia.- BMS + Acceleron
-Bristol Myers Squibb and Acceleron Pharma Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion,… read more.